Skip to main content
SpringerLink
Log in

TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Esophageal squamous cell carcinoma (ESCC) is an important cause of cancer-related death worldwide. To improve prognoses in patients with ESCC, we evaluated the potential of transforming growth factor-beta-induced protein (TGFBI), which is overexpressed in ESCC, as a therapeutic candidate.

Methods

We examined the clinical significance of TBFBI in 102 ESCC samples using real-time RT-PCR. Immunohistochemical studies were conducted to examine the localization of TGFBI. Knockdown of TGFBI in cocultured fibroblasts was performed to determine the roles of TGFBI in migration and invasion.

Results

The level of TGFBI in ESCC tissues was higher than that in normal tissues. The high TGFBI expression group (n = 16) had higher TGFB1 expression and more frequent hematogenous recurrence than the low-expression group (n = 86). High TGFBI expression was an independent prognostic factor in patients with ESCC. TGFBI was mainly localized in stromal cells of ESCC. Moreover, suppression of TGFBI in fibroblasts inhibited the migration and invasion capacity of TE8 ESCC cells.

Conclusions

High TGFBI expression in ESCC tissues could be a powerful biomarker of poor prognosis and hematogenous recurrence. TGFBI in stromal cells might be a promising molecular target for ESCC treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, et al. Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Bray FI, Devesa SS. Cancer Burden in the Year 2000. The Global Picture. Eur J Cancer. 2001;37 Suppl 8:S4–66.

    Article  PubMed  Google Scholar 

  3. Wong FH, Huang CY, Su LJ, et al. Combination of Microarray Profiling and Protein-Protein Interaction Databases Delineates the Minimal Discriminators as a Metastasis Network for Esophageal Squamous Cell Carcinoma. Int J Oncol. 2009;34:117–128.

    PubMed  CAS  Google Scholar 

  4. Kawamoto T, Noshiro M, Shen M, et al. Structural and phylogenetic analyses of RGD-CAP/Beta ig-h3, a Fasciclin-like adhesion protein expressed in chick chondrocytes. Biochim Biophys Acta. 1998;1395:288–92.

    Article  PubMed  CAS  Google Scholar 

  5. Schneider D, Kleeff J, Berberat PO, et al. Induction and Expression of Betaig-h3 in Pancreatic Cancer Cells. Biochim Biophys Acta. 2002;1588:1–6.

    Article  PubMed  CAS  Google Scholar 

  6. Nabokikh A, Ilhan A, Bilban M, et al. Reduced TGF-Beta1 expression and its target genes in human insulinomas. Exp Clin Endocrinol Diabetes. 2007;115:674–82.

    Article  PubMed  CAS  Google Scholar 

  7. Buckhaults P, Rago C, St Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001;61:6996–7001.

  8. Tomioka H, Morita K, Hasegawa S, Omura K. Gene Expression Analysis by cDNA Microarray in Oral Squamous Cell Carcinoma. J Oral Pathol Med. 2006;35:206–11.

    Article  PubMed  CAS  Google Scholar 

  9. Fujiki K, Nakayasu K, Kanai A. Corneal Dystrophies in Japan. J Hum Genet. 2001;46:431–5.

    Article  PubMed  CAS  Google Scholar 

  10. Han B, Luo H, Raelson J, et al. TGFBI (BetaIG-H3) is a diabetes-risk gene based on mouse and human genetic studies. Hum Mol Genet. 2014; 23:4597–611.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Li B, Wen G, Zhao Y, et al. The role of TGFBI in mesothelioma and breast cancer: association with tumor suppression. BMC Cancer. 2012;12:239.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  12. Wen G, Hong M, Li B, et al. Transforming growth factor-beta-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway. Int J Oncol. 2011;39:1001–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  13. Kang S, Dong SM, Park NH. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer. Gynecol Oncol. 2010;118:58–63.

    Article  PubMed  CAS  Google Scholar 

  14. Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer. 2008;8:284.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Caren H, Djos A, Nethander M, et al. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer. 2011;11:66.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Ahmed AA, Mills AD, Ibrahim AE, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to Paclitaxel. Cancer Cell. 2007;12:514–27.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein Betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 2008;22:308–21.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lebdai S, Verhoest G, Parikh H, et al. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol. 2014. doi:10.1016/j.urolonc.2014.06.005

  19. Skonier J, Neubauer M, Madisen L, et al. cDNA cloning and sequence analysis of Beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-Beta. DNA Cell Biol. 1992;11:511–22.

    Article  PubMed  CAS  Google Scholar 

  20. Ivanov SV, Ivanova AV, Salnikow K, et al. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun. 2008;370:536–40.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Montorfano I, Becerra A, Cerro R, et al. Oxidative stress mediates the conversion of endothelial cells into myofibroblasts via a TGF-Beta1 and TGF-Beta2-dependent pathway. Lab Invest 2014;94:1068–1082.

    Article  PubMed  CAS  Google Scholar 

  22. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Sem Cancer Biol. 2014;25:23–32.

    Article  CAS  Google Scholar 

  23. Ween MP, Oehler MK, Ricciardelli C. Transforming growth factor-beta-induced protein (TGFBI)/(Betaig-H3): a matrix protein with dual functions in ovarian cancer. Int J Mol Sci. 2012;13:10461–77.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  24. Jiang SS, Huang SF, Huang MS, et al. Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*. Biochim Biophys Acta. 2014;1842:1080–7.

    Article  PubMed  CAS  Google Scholar 

  25. Son HN, Nam JO, Kim S, Kim IS. Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind alphavbeta3 integrin, leading to anti-angiogenic and anti-tumor effects. Biochim Biophys Acta. 2013;1833:2378–88.

    Article  PubMed  CAS  Google Scholar 

  26. Lauden L, Siewiera J, Boukouaci W, et al. TGF-beta-induced (TGFBI) protein in melanoma: a signature of high metastatic potential. J Invest Dermatol. 2014;134:1675–85.

    Article  PubMed  CAS  Google Scholar 

  27. Klein CA. Cancer. The metastasis cascade. Science. 2008;321:1785–7.

    Article  PubMed  CAS  Google Scholar 

  28. Buga AM, Margaritescu C, Scholz CJ, et al. Transcriptomics of post-stroke angiogenesis in the aged brain. Front Again Neurosci. 2014;6:44.

    Google Scholar 

Download references

Acknowledgment

The authors thank Ms. Yukie Saito, Ms. Tomoko Yano, Ms. Yuka Matsui, Ms. Ayaka Ishida, and Ms. Ayaka Ishikubo for their assistance. This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), Grant Numbers 21591690, 22591450, and 23591857.

Author information

Authors and Affiliations

  1. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan

    Daigo Ozawa MD, Takehiko Yokobori MD, PhD, Makoto Sohda MD, PhD, Makoto Sakai MD, PhD, Keigo Hara MD, Hiroaki Honjo MD, Tatsuya Miyazaki MD, FACS & Hiroyuki Kuwano MD, FACS

  2. First Department of Surgery, Dokkyo Medical University, Mibu, Japan

    Hiroyuki Kato MD, FACS

Authors
  1. Daigo Ozawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takehiko Yokobori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Sohda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Sakai MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keigo Hara MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroaki Honjo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Kato MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatsuya Miyazaki MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Kuwano MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daigo Ozawa MD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 22 kb)

Supplementary material 2 (PDF 1241 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ozawa, D., Yokobori, T., Sohda, M. et al. TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 23, 282–289 (2016). https://doi.org/10.1245/s10434-014-4259-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4259-4

Keywords

Search

Navigation